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Abstract—Recently, we have reported that asthma is associated with enhanced plasma thrombin for-
mation and impaired fibrinolysis. The mechanisms underlying the prothrombotic state in this disease are
unknown. Our aim was to investigate whether prothrombotic alterations in asthmatics are associated
with inflammation. We studied 164 adult, white, stable asthmatics and 72 controls matched for age, sex,
body mass index (BMI), and smoking. Plasma tumor necrosis factor α (TNFα), interleukin (IL)-6, and
serum periostin were evaluated using ELISAs, and their associations with thrombin generation, fibri-
nolytic capacity, expressed as clot lysis time (CLT), and platelet markers were later analyzed. Asthma
was characterized by 62% higher plasma IL-6 and 35% higher TNFα (both, p < 0.0001). Inflammatory
cytokines were higher in sporadic and persistent asthmatics compared to controls, also after adjustment
for potential confounders. IL-6 was inversely related to the forced expiratory volume in 1 s/vital capacity
(FEV1/VC) spirometry index after correction for age, sex, and BMI. IL-6 and TNFα were associated
with C-reactive protein in asthmatics (β = 0.6 [95% CI, 0.54–0.67] and β = 0.33 [95% CI, 0.25–0.41],
respectively) and controls (β = 0.43 [95% CI, 0.29–0.57] and β = 0.33 [95% CI, 0.18–0.48], respec-
tively). In asthma, IL-6 and TNFα positively correlated with the endogenous thrombin potential
(β = 0.35 [95% CI, 0.28–0.42] and β = 0.15 [95% CI, 0.07–0.23], respectively) but not with CLT or
platelet markers. However, TNFα predicted CLT in a multiple linear regressionmodel. Periostin was not
associated with any hemostatic parameters. Enhanced thrombin generation is driven in asthma by a
systemic inflammatory state mediated by IL-6 and to a lesser extent TNFα, however, not periostin.
TNFα might contribute to impaired fibrinolysis.
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INTRODUCTION
Inflammation and coagulation are biological process-
es that might interact with each other in physiological and
pathological conditions [1]. Asthma is a heterogeneous
disease, characterized by chronic airway inflammation,
responsible for bronchial reversible obstruction and
hyper-responsiveness [2]. There is growing evidence for
heightened activation of blood coagulation in the airways
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of asthmatic subjects and procoagulant plasma protein
leakage into bronchoalveolar space [3]. However, it is not
known whether this local phenomenon might affect blood
coagulation and/or clinical symptoms in asthma patients. A
hemostatic imbalance in asthma has been postulated after a
rising number of reports on the increased risk of thrombo-
embolic events in asthmatics [4–7]. Recently, we have
investigated parameters of blood coagulation, platelet acti-
vation, and fibrinolysis in a large cohort of asthmatics and
demonstrated that this disease is characterized by enhanced
plasma thrombin formation, associated with impaired clot
lysis and blood platelet activation [8]. Prothrombotic state
in asthmatics has also been documented by Sneeboer et al.
[9], who showed increased thrombin generation, together
with higher levels of plasminogen activator inhibitor-1
(PAI-1), D-dimer, von Willebrand factor, and plasmin-α2-
antiplasmin complexes in this disease. In our study, the
hypercoagulable state in asthma was potently and indepen-
dently determined by increased blood C-reactive protein
(CRP) concentrations [8]. Based on this finding, we hy-
pothesized that a hypercoagulable state in asthma is related
to the systemic inflammatory response largely mediated by
interleukin (IL)-6, which is the most important inducer of
the synthesis of acute phase proteins, including CRP [10].
Mononuclear phagocytes are the main source of IL-6;
however, it is also produced by other inflammatory cells
participating in asthma pathology, such as T and B lym-
phocytes, fibroblasts, and endothelial cells [10]. It has been
shown that IL-6 might even be higher in the blood of
asymptomatic asthmatics [11]. Moreover, clinical and lab-
oratory data revealed that this cytokine is involved in the
activation of the blood coagulation pathway. An intrave-
nous bolus infusion of IL-6 in humans induced an increase
in the plasma thrombin-antithrombin complexes and the
prothrombin activation fragments F1+2, but it had no
impact on fibrinolysis [12]. It has been also demonstrated
that IL-6 levels in acute coronary syndrome are associated
with prothrombotic plasma thrombin generation profile
[13].
Tumor necrosis factor α (TNFα) is another cell sig-
naling cytokine that rises in the acute phase reaction [10].
This cytokine interacts with endothelial cells permitting the
egress on granulocytes into inflammatory loci and activa-
tion of these cells [10]. In healthy humans, the neutraliza-
tion of endogenous TNFα attenuated a severe systemic
inflammatory response, including cytokine release and
activation of neutrophils [14]. In addition to mononuclear
phagocytic cells, TNFα may be produced by neutrophils,
activated lymphocytes, natural killer cells, endothelial
cells, and mast cells; all of them are involved in the
pathogenesis of asthma. TNFα was higher in severe asth-
matics as compared to mild-moderate asthma subjects and
controls [15]. This cytokine also has some prothrombotic
properties. A single intravenous injection of recombinant
TNFα into normal humans induced an early activation of
factor (F)X, followed by a potent activation of prothrom-
bin, probably via the release of tissue factor (TF) [16].
TNFα might also be involved in the regulation of fibrino-
lysis. Infusion of recombinant TNFα in human volunteers
induced initial activation and subsequent inhibition of
plasmin generation [17]. In patients with cancer, TNFα
was capable of eliciting the release of a tissue-type plas-
minogen activator (tPA), urokinase-type plasminogen acti-
vator (uPA), and PAI-1 into circulation, indicative of the
activation and rapid inactivation of fibrinolysis [18].
Periostin is an extracellular matrix protein that is
generated, e.g., by airway epithelial cells in response to
IL-13. Serum periostin has been shown as an emerging
biomarker of T helper type 2 (Th2)-driven inflammation,
which is strongly associated with airway eosinophilia in
severe asthma [19, 20]. To our knowledge, there have been
no published studies analyzing the potential impact of
periostin on blood coagulation; however, Th2 cytokines
(i.e., IL-4, IL-10, and IL-13) were shown to inhibit this
process [21].
In the present study, we tested the hypothesis that an
enhanced inflammatory state detectable in peripheral blood
is associated with prothrombotic alterations observed in the
circulating blood of asthmatics. Moreover, we speculated
that Th2-driven inflammation, reflected by periostin con-
centrations, is involved in the prothrombotic state in this
disease. Therefore, we investigated the associations be-
tween the previously analyzed parameters of a
prothrombotic state in asthma [8] and concentrations of
IL-6 and TNFα and periostin in peripheral venous blood.
MATERIALS AND METHODS
Patients and Controls
We studied 164 white adult patients with clinically
stable asthma and 72 control subjects matched for sex, age,
bodymass index (BMI), and smoking habits. Inclusion and
exclusion criteria were described previously [8]. Briefly,
diagnosis of asthma was established based on a history of
recurrent respiratory symptoms, including wheezing,
shortness of breath, chest tightness, and cough, together
with the documented post-bronchodilator increase in
forced expiratory volume in 1 s (FEV1) of at least 12%
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and 200 ml from the baseline. Atopic status was confirmed
by a positive skin prick testing for at least one inhaled
allergen (Allergopharma, Reinbeck, Germany). Allergic
asthma was diagnosed if the relevance of allergen exposure
and its relation to symptoms were confirmed by the pa-
tient’s history [22]. All asthma medications, with the ex-
ception of omalizumab, were permitted. Asthma patients
could not be exacerbated during the preceding 6 months.
Severity of asthmawas categorized according to the Global
Initiative for Asthma (GINA) guidelines [22]. Spirometry
was performed using a Jaeger, Master Screen spirometer
on all enrolled subjects according to the American Thorac-
ic Society standards. If basal spirometry showed bronchial
obstruction, the bronchial reversibility test with 400 μg of
albuterol was performed and parameters of the second
spirometry were analyzed for further investigation.
Control subjects matched for age, sex, BMI, and
smoking by frequency were enrolled from hospital person-
nel and relatives; all had normal spirometry and no history
of allergic diseases or bronchial obstruction in the past.
The study was approved by the Ethics Committee of
the Jagiellonian University.
Informed Consent. Informed consent was obtained
from all individual participants included in the study.
Laboratory Investigations
Fasting blood samples were drawn from the antecubital
vein using minimal stasis between 8:00 and 11:00 A.M.
Lipid profile, glucose, creatinine with estimated glomerular
filtration rate, alanine aminotransferase, blood cell, and
platelet count were assayed by routine laboratory tech-
niques. Fibrinogen, high-sensitivity (hs) CRP, and immuno-
globulin E (IgE) were measured as previously described [8].
Blood samples were drawn into tubes containing 0.109 mol/
l sodium citrate (vol/vol, 9:1) and serum separation tubes,
centrifuged 2000×g for 20 min at room temperature, within
2 h from sampling. The supernatant was frozen in aliquots
and stored at −70 °C until analysis.
Commercially available immunoenzymatic assays
were used to measure IL-6 and TNFα (R&D Systems,
Minneapolis, MN, USA), as well as periostin (Phoenix
Pharmaceuticals, Burlingame, CA, USA).
Methodology to determine plasma plasminogen, α2-
antiplasmin, prothrombin, antithrombin, PAI-1, platelet fac-
tor 4 (PF4), and P-selectin, as well as determination of α2-
macroglobulin, and clot lysis time (CLT), a global test of
plasma fibrinolytic potential, was described previously [8].
To assess thrombin generation, we used the calibrated
automated thrombogram (CAT) with computational model
of thrombin dynamics and analyzed, i.e., the maximum
concentration of thrombin formed during the recording
time (described as the Bthrombin peak^) and the area under
the curve which represents the Bendogenous thrombin
potential^ (ETP), as described [8, 23].
Statistical Analysis
The assumption of normality was verified with the
Shapiro-Wilk test. All continuous variables were non-
normally distributed and presented as median with upper
and lower quartile. On figures, they were shown as median
with interquartile range and maximum and minimum
values. Continuous variables were compared by the
Mann-Whitney U test, Kruskal-Wallis, and multiple repe-
tition tests, as appropriate, while categorical variables by
χ2 test. To test the relationship between continuous
variables, the univariate linear regression model was
used. Because IgE had a skewed distribution, a 10 log-
transformed was entered for a better fit of the model. Other
variables were calculated in the original scale. The strength
of the association of IL-6 and TNFα with ETP was ana-
lyzed by the test comparing the correlation coefficients.
Independent determinants of CLT and ETP were
established in a multiple linear regression model, built by
a forward stepwise selection procedure, and verified by F
Snedecor’s statistics, with F > 1. The R2 was used as a
measure of the variance. Log-linear analysis and uncondi-
tional multivariate logistic regression were performed to
make adjustments for categorical variables (age [cut-off
value of 50 years], sex, BMI [<25 and ≥25 kg/m2],
hypertension, diabetes mellitus, coronary heart disease,
smoking, and medications used, i.e., statins, aspirin,
antihypertensives, corticosteroids, montelukast,
theophylline, and oral estrogens). To calculate odds ratios
(ORs) with 95% confidence intervals (CIs), TNFα and IL-
6 were divided using the value of 75th percentile in con-
trols as a cut-off point.
P values <0.05 were considered statistically signifi-
cant. Analysis was performed with STATISTICA 10.0
software package (StatSoft, Inc., Tulsa, OK, USA).
RESULTS
Patient Characteristics
Demographic and clinical characteristics of the sub-
jects studied were given in detail in our previous
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publication [8]. Briefly, asthmatics and controls were well
matched for age (53.5 [38.5–63] and 50.5 [39–58] years,
p = 0.34), sex (male-to-female ratio 25.6 and 25%,
p = 0.92), and BMI (26.6 [23.9–29.7] and 25.6 [23.2–
29.1] kg/m2, p = 0.15), as well as other cardiovascular
risk factors, including smoking habits and co-morbidities.
Most asthmatics represented overweight, middle-aged
women, with a predominance of allergic asthma (n = 94,
57.3%). The latter patients were younger, more often male
with a lower prevalence of hypertension compared with
non-allergic asthmatics. Twenty asthmatics (12.2%) were
diagnosed with sporadic asthma, 36 (21.9%) with persis-
tent mild, 45 (27.4%) with moderate, while 63 (38.4%) had
severe asthma.
All persistent asthmatics (n = 144, 87.8%) received
ICS, 124 (75.6%) long-acting β2-agonists, 40 (24.4%)
montelukast, 26 (15.8%) theophylline, and 34 (20.7%) oral
corticosteroids. All asthmatics on theophylline and all but
one subject on montelukast received inhaled corticoste-
roids. Ten patients on montelukast (25%) and 13 on the-
ophylline (50%) were also treated with oral corticosteroids.
Laboratory Variables
Asthmatics had higher inflammatory markers, i.e.,
hsCRP and fibrinogen, as well as α2-macroglobulin and
PF4, compared with the control subjects (Table 1). Asthma
was characterized by markedly increased ETP (1508.3
Table 1. A Summary of Selected Laboratory Variables in the Subjects Studied
Asthma
patients
n = 164
Control
subjects
n = 72
p value
asthma vs.
controls
Allergic
asthma
n = 94
p value
a l l e r g i c
a s t hma v s .
controls
Non-allergic
asthma
n = 70
p value
n o n - a l l e r g i c
a s t h m a v s .
controls
p value
allergic vs. non-
allergic asthma
hsCRP, mg/l 1.27 (0.59–
2.55)
0.87
(0.2-
9–
2.9)
0.03 1.21 (0.56–
2.3)
0.34 1.85 (0.62–
2.78)
0.04 0.67
Fibrinogen, g/l 3.6 (3.0–
3.95)
3.36
(2.7-
3–
3.57)
0.001 3.5 (3.0–3.9) 0.03 3.65 (3.1–
4.1)
0.004 0.39
α2-
macroglobu-
lin, nmol/l
3.7 (3.23–
4.22)
3.29
(2.8-
9–
3.57)
0.0002 3.78 (3.36–
4.30)
<0.0001 3.54 (3.04–
4.22)
0.02 0.22
Platelet factor 4,
ng/ml
146.65
(129.87–
156.91)
97 (87–
112.-
5)
<0.0001 148.29
(129.61–
157.85)
<0.0001 144.96
(130.13–
156.49)
<0.0001 0.62
Immunoglobulin
E, IU/ml
1.92 (1.37–
2.37)
1.5
(1.3-
9–
1.84)
0.003 2.26 (1.91–
2.61)
<0.0001 1.29 (1.24–
1.68)
0.23 <0.0001
Eosinophils, /ul 166 (100–
300)
ND NA 180 (80–
300)
NA 140 (100–
250)
NA 0.7
Interleukin 6, pg/
ml
4.55 (3.58–
5.73)
3.06
(2.5-
6–
4.1)
<0.0001 4.43 (3.45–
5.6)
<0.0001 4.83 (3.87–
5.86)
<0.0001 0.14
Tumor necrosis
factor α, pg/
ml
3.93 (3–4.7) 2.91
(2.2-
6–
3.7)
<0.0001 4.02 (3.02–
4.75)
<0.0001 3.8 (2.91–
4.69)
<0.0001 0.69
Periostin, ng/ml 0.44 (0.32–
0.6)
ND NA 0.41 (0.32–
0.56)
NA 0.45 (0.34–
0.7)
NA 0.3
Data is presented as median with upper and lower quartiles
ND not done, NA not applicable, hsCRP high-sensitivity C-reactive protein, n number
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[1342–1680.7] vs. 1255 [1078.6–1454.2] nmol/l thrombin
min, p < 0.0001), higher thrombin peak (283.6 [244.3–
328.5] vs. 200.5 [154.1–229.6] nmol/l, p < 0.0001), faster
rate of thrombin formation (time to peak) (5 [4.67–6] vs.
5.92 [5.17–7.13] min, p < 0.0001), together with higher
total amount of prothrombin converted (904.7 [797–1026]
vs. 848.1 [739.4–937] nmol/l, p = 0.03), and lower throm-
bin inactivation capacity (thrombin decay capacity) (0.63
[0.58–0.69] vs. 0.7 (0.6–0.75) min−1, p = 0.0004), as
compared with control subjects. We observed impaired
fibrinolysis in asthmatics, reflected by longer CLT (95.2
[71–117.4] vs. 83.2 [71.45–99] min, p = 0.001), and
accompanied with higher plasminogen (106.7 [94.5–19]
vs. 102.4 [96.5–107] %, p = 0.02) and PAI-1 (29.48
[21.74–42.54] vs. 24.3 [18.7–29.75] ng/ml, p < 0.0001),
but unaltered antiplasmin (103 [96–114] vs. 100.3 [90.6–
110.5] %, p = 0.09).
Inflammatory Cytokines
In asthma, we demonstrated 62% higher plasma
levels of IL-6 and 35% higher TNFα, also after adjustment
for potential confounders (β = 0.43 [95% CI, 0.37–0.49]
and β = 0.37 [95% CI, 0.31–0.43], respectively). There
were no differences between allergic and non-allergic sub-
jects in the two cytokines (Table 1). Plasma IL-6 and TNFα
were higher in persistent and sporadic asthmatics (Figs. 1
and 2). As shown in Table 2, asthmatics had a markedly
higher risk of elevated IL-6 (OR 5.48 [95% CI, 4.7–7.0])
and TNFα (OR 3.93 [95% CI, 2.8–5.1]), compared with
the controls (cut-offs, 4.08 and 3.66 pg/ml, respectively).
Aweak, but significant, inverse association was doc-
umented in asthmatics between IL-6 and the FEV1/VC
ratio, also after adjustment for potential confounders
(β = −0.13 [95% CI, −0.2 to −0.05]). IL-6 was associated
in the asthma group with age (β = 0.19 [95% CI, 0.11–
0.27]) and BMI (β = 0.25 [95% CI, 0.17–0.32]), as well as
hsCRP (β = 0.6 [95%CI, 0.54–0.67]), fibrinogen (β = 0.29
[95% CI, 0.22–0.37]), TNFα (β = 0.29 [95% CI, 0.22–
0.37]), and ETP (β = 0.35 [95% CI, 0.28–0.42]).
Among all parameters describing computational assess-
ment of thrombin dynamics, IL-6 was associated only with
thrombin-α2-macroglobulin complex formation (β = 0.19
[95% CI, 0.11–0.28]). On the other hand, none of the studied
fibrinolytic parameters were related to this cytokine.
Co-morbidities did not influence IL-6 levels, but its
higher values were observed in asthmatics receiving estro-
gens (n = 19, 5.24 [4.38–7.48] vs. 4.51[3.48–5.64] pg/ml,
p = 0.04), beta adrenoreceptor antagonists (n = 21, 5.5
[4.43–6.98] vs. 4.51 [3.48–5.62] pg/ml, p = 0.01), and
montelukast (n = 40, 5.16[4.05–6.24] vs. 4.5[3.46–5.48]
pg/ml, p = 0.04). Higher IL-6 in asthma subjects on
antileukotriene medication was also documented after ad-
justment for asthma severity and other potential con-
founders (β = 0.17 [95% CI, 0.09–0.25]).
IL-6 was associated with hsCRP in the control group
(β = 0.43 [95% CI, 0.29–0.57]), TNFα (β = 0.43 [95% CI,
0.32–0.54]), and prothrombin activity (β = 0.31 [95% CI,
0.17–0.45]), as well as maximum prothrombin conversion rate
(β = 0.27 [95% CI, 0.15–0.38] and thrombin-antithrombin
complex formation (β = 0.29 [95% CI, 0.14–0.44]).
Fig. 1. Distribution of interleukin 6 in controls and patients with intermit-
tent, persistent mild, moderate, and severe asthma. Data is presented as
median, interquartile range, and maximum andminimum values. Numbers
on the graph represent p values in comparison to control. Statistically si-
gnificant differences are marked with an asterisk.
Fig. 2. Distribution of tumor necrosis factor α in controls and patients
with intermittent, persistent mild, moderate, and severe asthma. Data is
presented as median, interquartile range, and maximum and minimum v-
alues. Numbers on the graph represent p values in comparison to control.
Statistically significant differences are marked with an asterisk.
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As expected, TNFα was associated with hsCRP in
asthmatics (β = 0.33 [95% CI, 0.25–0.41]) and controls
(β = 0.33 [95%CI, 0.18–0.48]). In asthma only, however, this
cytokine was related to the prothrombin activity (β = 0.18
[95%CI, 0.1–0.26]), ETP (β= 0.15 [95%CI, 0.07–0.23]), and
thrombin peak (β = 0.16 [95% CI, 0.08–0.23]). All these
associations remained significant after correction for BMI,
age, and sex in linear regression models. The magnitude of
the impact of IL-6 on ETP, compared with that of TNFα, was
larger (p = 0.03).Moreover, a multiple linear regressionmodel
showed that several laboratory parameters independently de-
termined ETP in asthmatics, including hsCRP (β = 0.13 [95%
CI, 0.03–0.23]) and IL-6 (β = 0.17 [95% CI, 0.08–0.26]) but
not TNFα (Table 3).
Among parameters describing computational assess-
ment of thrombin dynamics, TNFα was related in asth-
matics only to the thrombin-α2-macroglobulin complex
formation (β = 0.15 [95% CI, 0.06–0.24]), while in con-
trols, it was associated with the total prothrombin convert-
ed and thrombin-antithrombin complex formation
(β = 0.31 [95% CI, 0.16–0.46], both).
In both groups of subjects, there were no associations of
TNFαwith platelet activation markers, as well as CLT, PAI-1,
and antiplasmin. Aweak inverse relationship was documented
for TNFα and plasminogen in asthma (β = −0.1 [95% CI,
−0.18 to −0.03]) and in the controls (β = −0.26 [95% CI,
−0.38 to −0.15]). However, as shown in Table 3, multiple
linear regressionmodels demonstrated that TNFαmight be an
independent predictor of longer CLT in asthma and control,
although a direct association between both these variables was
not documented in linear univariate regression models.
Medications used and co-morbidities analyzed sepa-
rately had no impact on plasma TNFα. However, men with
arterial hypertension (n = 16) had higher levels of TNFα
than those without this co-morbidity (n = 26), (4.53 [3.57–
5.05] vs. 3.8 [3.12–4.5] pg/ml, p = 0.03).
Periostin
Serum concentration of periostin was measured only in
asthmatics. Patients treated with oral corticosteroids (n = 34)
had lower periostin levels than those not receiving this
medication (0.35 [0.3–0.48] vs. 0.45 [0.33–0.73] ng/ml,
p = 0.02). Other asthma medications and co-morbidities
had no impact on periostin concentration. There was no
difference among all asthma severity groups after the exclu-
sion of subjects receiving oral corticosteroids. Periostin did
not correlate with eosinophilia, blood IgE, or other basic
laboratory tests. A positive association of periostin with α2-
macroglobulin was observed also after correction for potential
confounders (β = 0.16 [95% CI, 0.07–0.26]). There were
inverse correlations of periostin with blood platelet count
(β = −0.12 [95% CI, −0.21 to −0.04]) and total cholesterol
(β = −0.27 [95% CI, −0.36 to −0.18]).
Table 2. Odds Ratios (ORs) with 95% Confidence Intervals (95% CI) for Asthmatics of Having Interleukin 6 and Tumor Necrosis Factor α Above 75th
Percentile of Control Values with Subjects Below This Cutoff Point as a Reference Group, with Adjustment for Age, Sex, and Body Mass Index
Interleukin 6 >4.08 pg/ml (75th percentile
of the control values)
Tumor necrosis factor α >3.66 pg/ml (75th percentile
of the control values)
Control, numbers 18 18
Asthma, numbers 106 93
OR (95% CI) 5.48* (4.7–7.0) 3.93* (2.8–5.1)
Allergic asthma, numbers 55 56
OR (95% CI) 4.23* (3.1–5.4) 4.42* (3.2–5.6)
Non-allergic asthma, numbers 51 37
OR (95% CI) 8.05* (6.8–10.9) 3.36* (2.2–4.5)
<50 years ≥50 years <50 years ≥50 years
Control, numbers 12 6 7 11
Asthma, numbers 39 67 35 58
OR (95% CI) 2.6* (1.4–3.77) 11.96 *(9.8–14.1) 4.26* (2.78–5.74) 3.56* (2.34–4.78)
Men Women Men Women
Control, numbers 4 14 4 14
Asthma, numbers 26 80 26 67
OR (95% CI) 5.69* (3.4–7.9) 5.44* (4.2–6.7) 5.69* (3.4–7.9) 3.48* (2.44–4.52)
Body mass index <25 Body mass index ≥25 Body mass index <25 Body mass index ≥25
Control, numbers 9 9 8 10
Asthma, numbers 43 63 37 56
OR (95% CI) 5.16* (3.5–6.8) 5.73* (4.2–7.2) 4.18* (2.71–5.65) 3.64* (2.42–4.86)
* Statistically significant
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DISCUSSION
The present study is the first to show that a hyperco-
agulable state in asthma, characterized by enhanced plasma
thrombin formation, is associated with increased blood
levels of inflammatory cytokines, IL-6 and TNFα. This
indicates that the systemic low-grade inflammatory state
contributes to the activation of blood coagulation in asth-
matics, providing additional evidence for close links be-
tween inflammation and coagulation. We found no
Table 3. Multiple Linear Regression Models for Endogenous Thrombin Potential and Clot Lysis Time Taking into Account Interleukin 6, Tumor Necrosis
Factor α, and Periostin
Endogenous thrombin potential
Control Asthma
β 95% CI R2 β 95% CI R2
Age, years 0.4 0.03 −0.05 to 0.11 0.37
Body mass index, kg/m2 0.16a 0.01 to 0.31 0.2a 0.12 to 0.28
FEV1/VC –0.09
a −0.17 to −0.01
Blood platelet count, 103/μl 0.17a 0.09 to 0.25
Total cholesterol, mmol/l 0.16a 0.08 to 0.24
Factor II, % 0.38a 0.23 to 0.53 0.19a 0.12 to 0.26
hsCRP, mg/l 0.15 −0.01 to 0.31 0.13a 0.03 to 0.23
Immunoglobulin E (log10), IU/ml 0.26a 0.12 to 0.40
Interleukin 6, pg/ml 0.01 −0.16 to 0.18 0.17a 0.08 to 0.26
Tumor necrosis factor α, pg/ml 0.07 −0.08 to 0.22 0.04 −0.04 to 0.12
Periostin, ng/ml 0.02 −0.06 to 0.1
α2-macroglobulin, nmol/l 0.30
a 0.14 to 0.45 0.34a 0.27 to 0.41
Plasminogen, % 0.09a 0.02 to 0.16
Platelet factor 4, ng/ml 0.01 −0.06 to 0.8
Adjustment statistics F = 3.29, p = 0.009 F = 6.9, p < 0.001
Clot lysis time
Control Asthma
β 95% CI R2 β 95% CI R2
FEV1/VC 0.51 −0.11a −0.19 to −0,03 0.25
Blood platelet count, 103/μl 0.14a 0.01 to 0.27
White blood cells, 103/μl 0.15a 0.03 to 0.27 0.01 −0.07 to 0.09
Total cholesterol, mmol/l 0.13a 0.01 to 0.25 0.15a 0.07 to 0.23
Triglycerides, mmol/l 0.19a 0.16 to 0.31
Glucose, mmol/l 0.2a 0.06 to 0.34
hsCRP, mg/l −0.21a −0.35 to −0.07 0.08 −0.02 to 0.18
Immunoglobulin E (log10), IU/ml −0.23a −0.31 to −0.15
Antithrombin, % −0.11a −0.19 to −0,03
ETP, nmol/l thrombin x min. −0.21a −0.33 to −0.09 0.17a 0.12 to 0.26
Plasminogen, % 0.2a 0.08 to 0.32 0.06 −0.02 to 0.14
Interleukin 6, pg/ml −0.002 −0.152 to 0.148 −0.05 −0.15 to 0.05
Tumor necrosis factor α, pg/ml 0.31a 0.16 to 0.46 0.15a 0.07 to 0.23
Periostin, ng/ml 0.04 −0.04 to 0.12
Antiplasmin, % 0.3a 0.17 to 0.43
Plasminogen activator inhibitor-1, ng/ml 0.35a 0.22 to 0.48 0.28a 0.2 to 0.36
P-selectin, ng/ml −0.26a −0.4 to −0.12 −0.2a −0.28 to −0.12
Adjustment statistics F = 4.2, p = 0.0006 F = 4.37, p < 0.001
The resulting standardized regression coefficient (β) (with 95% confidence intervals [95% CI]) for a factor (independent variable) indicates the increase/
decrease in standard deviations (SDs) of dependent variable, when that particular factor increases with 1 SD and all other variables in the model are
unchanged
FEV1/VC forced expiratory volume in 1 s/vital capacity, hsCRP high-sensitivity C-reactive protein, ETP endogenous thrombin potential
a Statistically significant
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evidence for the involvement of periostin, a marker of
Th2-mediated activation, in the prothrombotic alterations in
asthma. The current study indicates that asthma, like other
inflammatory diseases, e.g., chronic obstructive pulmonary
disease or inflammatory bowel disease [24, 25], is associated
with prothrombotic changes in circulating blood that are
largely driven by acute phase inflammatory mechanisms.
Inflammatory Cytokines
We have shown in this study that IL-6 and TNFα
were higher in asthmatics and associated with the total
amount of thrombin generated using the well-established
CAT assay. The effect of IL-6 on thrombin formation was
stronger in asthmatics than that observed for TNFα. This
indicates that IL-6-mediated inflammation is a major driver
of increased hypercoagulability in asthma, similarly to
several other diseases including atherosclerotic vascular
disease [26–28]. It remains to be established, however,
whether asthma also predisposes to this disease [29, 30].
The precise mechanisms underlying the associations
between inflammatory cytokines and thrombin formation
in asthma remain unclear. The most tempting hypothesis
might be that systemic inflammation largely driven by IL-6
and reflected by elevated CRP stimulates the activation of
procoagulant mechanisms, leading to the enhanced throm-
bin formation, as it was shown in subjects with acute
coronary syndrome [13]. IL-6 inter alia induces fibrinogen
synthesis by hepatocytes and other cells and is involved in
iron dysregulation, in particular by its ability to induce
hepcidin biosynthesis [31]. Procoagulant effects of IL-6
and TNFα involve also an increased expression of TF on
monocytes, endothelial, dendritic, and vascular smooth
muscle cells [32, 33]. TF is a surface receptor for FVIIa
and plays a key role in the initiation of blood coagulation,
leading to thrombin formation [34]. The TF signaling
proceeds with the sequential generation of coagulant me-
diators (FVIIa, FXa, and FIIa: active serine proteases) and
fibrin production, all of which are procoagulant but also
proinflammatory [35]. A molecular link between coagula-
tion and inflammation might be explained by specific G
protein-coupled protease-activated receptors (PARs), des-
ignated PAR 1–4, which are expressed on variable airway
cells, including smoothmuscles and epithelial cells, as well
as inflammatory infiltrating cells (for review, see [35]).
Activation of these receptors by thrombin, FXa, and TF/
FVIIa leads to the overproduction of, e.g., IL-6, IL-8,
platelet-derived growth factor, and P-selectin and also
might participate in airway remodeling, another important
feature of asthma, which develops independently of
corticosteroid therapy and severity of bronchial inflamma-
tion [36, 37]. Notably, anticoagulant therapy is not used in
asthma treatment nowadays, although interventions with
anticoagulants such as fondaparinux (FXa inhibitor) and
hirudin (thrombin inhibitor), as well as the use of tPA and
uPA improved the disturbed pulmonary hemostatic balance
and concurrently diminished airway inflammation and im-
proved asthma parameters, including features of airway
remodeling, in experimental settings [3]. Favorable effects
of inhaled heparin on airway inflammation and asthma
symptoms observed in humans might be attributable in
part to the suppression of excessively enhanced thrombin
formation and elimination of harmful thrombin-mediated
cellular inflammatory effects [3].
In our previous study, we also employed a computational
analysis of thrombin generation curves to investigate the bal-
ance of pro- and anticoagulant mechanisms during thrombin
generation [8]. This equilibrium was extensively disturbed by
increased prothrombin conversion and reduced thrombin in-
activation in asthma patients. Surprisingly, both analyzed in-
flammatory cytokines in asthmatics were positively associated
only with thrombin-α2-macroglobulin complex formation.
This observation suggests that IL-6 and TNFαmight increase
the capacity to buffer active thrombin by its facilitated binding
to the α2-macroglobulin, which was also higher in asthmatics
than in the controls. This might suggest an unexpected anti-
inflammatory mode of action observed for the two cytokines.
Further studies are needed to validate this observation.
Inflammationmight have also an impact on decreased
clot susceptibility to lysis. Impaired fibrinolysis has been
documented in variable inflammatory diseases [38], in-
cluding asthma [8]. Clot formation is affected by a plethora
of circulating plasma molecules, e.g., IL-1, and its proper-
ties involving the pore size, fibrin diameter, rigidity, and
ease of fibrinolysis, which may vary in inflammation [38].
We did not observe any association between both inflam-
matory cytokines and CLT in our study, which is a global
plasma test of fibrinolysis successfully used in several
disease states to document impaired lytic mechanisms in
patients [39]. As we showed previously, impaired fibrino-
lysis in asthma was largely driven by increased PAI-1 [8].
In the present study, IL-6 and TNFα had no direct impact
on plasma PAI-1 antigen concentrations. However, a neg-
ative link between TNFα and plasminogen suggests that
this cytokine might also contribute, at least to some extent,
to the impaired fibrinolysis. This concept has been sup-
ported by constructed multiple linear regression models,
which demonstrated that TNFα in cooperation with other
laboratory variables affected CLT in asthmatics but also
(even stronger) in the controls. Our observation is in line
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with the result of in vivo experiments, in which the infusion
of recombinant TNFα was capable of eliciting the release
of PAI-1 into the circulation [18]. A mouse model showed
another piece of evidence for a potential link between PAI-
1and TNFα [40]. Inactivation of TNFα receptors results in
significantly reduced plasma PAI-1 levels in this study.
Periostin
Blood periostin levels in our study were not associat-
ed with asthma severity or eosinophilia. These findings are
in accordance with the results of Wagener et al. [41], who
found that the serum periostin was a weak predictor of
eosinophilic asthma in mild-to-moderate asthma. A similar
observation was published byGórska et al. [42]. This study
showed no difference in this protein between asthma and
control subjects, as well as no correlation with asthma
inflammatory type. In our data, periostin was also not
associated with any of the measured parameters of throm-
bin formation. A positive association of α2-macroglobulin
with periostin is a new observation, which requires a
comment. α2-macroglobulin functions as a universal pro-
tease inhibitor in blood and is capable of binding various
host or foreign peptides and particles, cytokines, and
growth factors. It serves as an unspecific defense barrier
against pathogens in the plasma and tissues [43]. A strong
association observed between periostin and α2-macroglob-
ulin might indicate that the excess of this protein would be
bound to the α2-macroglobulin.
Study Limitations
The study group was relatively small. We deter-
mined each variable at a single time point and therefore
we cannot exclude changes of the variables studied over
time. Periostin was measured only in asthmatics, which
made comparisons impossible between the studied
groups. We did not analyze Th2 cytokines, such as IL-4,
IL-5, or IL-13, and therefore we cannot exclude a certain
involvement of Th2 response in the regulation of blood
coagulation in asthma. The assessment of medication-
induced alterations to inflammatory markers was beyond
the scope of our study. Interestingly, we observed that
treatment with systemic corticosteroids was associated
with lower periostin levels, while those on montelukast
had higher IL-6 in plasma, independently from the asthma
severity and other potential confounders, including age,
BMI, or co-morbidities. Surprisingly, an unfavorable ef-
fect of antileukotriene medication was also observed in
relation to the ETP and CLT, as described in our previous
publication [8]. We did not determine other potential
modulators of coagulation and fibrinolysis, e.g., genetic
polymorphisms. Given prothrombotic abnormalities in
first-degree relatives of patients with venous thrombosis
[44], we cannot exclude that a prothrombotic state ob-
served in asthma is to some extent genetically determined
[45]. Statistical associations reported here may not nec-
essarily indicate cause-effect relationships. Finally, clin-
ical relevance of prothrombotic alterations in asthmatics
and their relation to the inflammation in terms of throm-
boembolic risk as well as their molecular mechanisms
remain to be established.
CONCLUSION
Our study demonstrates that enhanced thrombin gen-
eration in asthma might be a reason of systemic inflamma-
tory state and is, at least partially, driven by inflammatory
cytokines, such as IL-6 and TNFα. On the other hand,
impaired fibrinolysis is not directly associated with their
levels. Further studies are needed to better characterize
links between inflammation and prothrombotic alterations
in asthmatics.
COMPLIANCE WITH ETHICAL STANDARDS
Funding. This project was funded by the National
Science Centre based on decision No. DEC-2013/09/B/
NZ5/00758.
Conflict of Interest. The authors declare that they have
no conflict of interest.
Ethical Approval. All procedures performed in studies
involving human participants were in accordance with the
ethical standards of the institutional and/or national re-
search committee and with the 1964 Helsinki Declaration
and its later amendments or comparable ethical standards.
Open Access This article is distributed under the terms of
the Creative Commons Attribution 4.0 International Li-
cense (http://creativecommons.org/licenses/by/4.0/),
which permits unrestricted use, distribution, and reproduc-
tion in any medium, provided you give appropriate credit
to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes
were made.
1233Prothrombotic State in Asthma
REFERENCES
1. Van der Poll, T., E. de Jonge, and H. ten Cate. 2000–2013. Cyto-
kines as regulators of coagulation. In: Madame Curie Bioscience
Database [Internet]. Austin (TX): Landes Bioscience. Available
from: http://www.ncbi.nlm.nih.gov/books/NBK6207/. Accessed 14
July 2016.
2. Hartley, R., R. Berair, and C.E. Brightling. 2014. Severe asthma:
Novel advances in the pathogenesis and therapy. Polskie Archiwum
Medycyny Wewnętrznej 124: 247–254.
3. De Boer, J.D., C.J. Majoor, C. van’t Veer, E.H. Bel, and T. van der
Poll. 2012. Asthma and coagulation. Blood 119: 3236–3244.
4. Chung, W.S., C.L. Lin, F.M. Ho, R.Y. Li, F.C. Sung, C.H. Kao, and
J.J. Yeh. 2014. Asthma increases pulmonary thromboembolism risk:
A nationwide population cohort study. The European Respiratory
Journal 43: 801–807.
5. Majoor, C.J., P.W. Kamphuisen, A.H. Zwinderman, A. Ten Brinke,
M. Amelink, L. Rijssenbeek-Nouwens, P.J. Sterk, H.R. Büller, and
E.H. Bel. 2013. Risk of deep vein thrombosis and pulmonary embo-
lism in asthma. The European Respiratory Journal 42: 655–661.
6. Chung, W.S., C.L. Lin, Y.F. Chen, F.M. Ho, W.H. Hsu, and C.H.
Kao. 2014. Increased stroke risk among adult asthmatic patients.
European Journal of Clinical Investigation 44: 1025–1033.
7. Onufrak, S.J., J.L. Abramson, H.D. Austin, F. Holguin, W.M. Mc-
Clellan, and L.V. Vaccarino. 2008. Relation of adult-onset asthma to
coronary heart disease and stroke. The American Journal of Cardi-
ology 101: 1247–1252.
8. Bazan-Socha, S., L.Mastalerz, A. Cybulska, L. Zareba, R. Kremers,
M. Zabczyk, G. Pulka, T. Iwaniec, C. Hemker, and A. Undas. 2016.
Asthma is associated with enhanced thrombin formation and im-
paired fibrinolysis. Clinical and Experimental Allergy 46: 932–944.
doi:10.1111/cea.12734.
9. Sneeboer, M.M., C.J. Majoor, A. de Kievit, J.C. Meijers, T. van der
Poll, P.W. Kamphuisen, and E.H. Bel. 2016. Prothrombotic state in
patients with severe and prednisolone-dependent asthma. The Jour-
nal of Allergy and Clinical Immunology 137: 1727–1732.
doi:10.1016/j.jaci.2015.10.038.
10. Borish, L., and L.J. Rosenwasser. 2009. Cytokines in allergic in-
flammation. InMiddleton’s Allergy, Principles and Practice, ed. N.F.
Adkinson, B. Bochner, W. Busse, S. Holgate, R. Lemanske, and F.E.
Simons, 7th ed., 165–179. Philadelphia: Mosby Elsevier.
11. Yokoyama, A., N. Kohno, S. Fujino, H. Hamada, Y. Inoue, S.
Fujioka, S. Ishida, and K. Hiwada. 1995. Circulating interleukin-6
levels in patients with bronchial asthma. American Journal of Re-
spiratory and Critical Care Medicine 151: 1354–1358.
12. Stouthard, J.M., M. Levi, C.E. Hack, C.H. Veenhof, H.A. Romijn,
H.P. Sauerwein, and T. van der Poll. 1996. Interleukin-6 stimulates
coagulation, not fibrinolysis, in humans. Thrombosis and
Haemostasis 76: 738–742.
13. Undas, A., K. Szułdrzyński, K.E. Brummel-Ziedins, W. Tracz, K.
Zmudka, and K.G. Mann. 2009. Systemic blood coagulation activa-
tion in acute coronary syndromes. Blood 113: 2070–2078.
doi:10.1182/blood-2008-07-167411.
14. Van der Poll, T., M. Levi, S.J. van Deventer, H. ten Cate, B.L.
Haagmans, B.J. Biemond, H.R. Büller, C.E. Hack, and J.W. ten
Cate. 1994. Differential effects of anti-tumor necrosis factor mono-
clonal antibodies on systemic inflammatory responses in experimen-
tal endotoxemia in chimpanzees. Blood 83: 446–451.
15. Silvestri, M., M. Bontempelli, M. Giacomelli, M. Malerba, G.A.
Rossi, A. Di Stefano, A. Rossi, and F.L. Ricciardolo. 2006. High
serum levels of tumour necrosis factor-alpha and interleukin-8 in
severe asthma: Markers of systemic inflammation? Clinical and
Experimental Allergy 36: 1373–1381.
16. Van der Poll, T., H.R. Büller, H. ten Cate, C.H. Wortel, K.A. Bauer,
S.J.H. van Deventer, C.E. Hack, H.P. Sauerwein, R.D. Rosenberg,
and J.W. ten Cate. 1990. Activation of coagulation after administra-
tion of tumor necrosis factor to normal subjects. The New England
Journal of Medicine 322: 1622–1627.
17. Van der Poll, T., M. Levi, H.R. Büller, S.J.H. van Deventer, J.P. de
Boer, C.E. Hack, and J.W. ten Cate. 1991. Fibrinolytic response to
tumor necrosis factor in healthy subjects. The Journal of Experi-
mental Medicine 174: 729–732.
18. Van Hinsbergh, V.W., K.A. Bauer, T. Kooistra, C. Kluft, G.
Dooijewaard, M.L. Sherman, and W. Nieuwenhuizen. 1990. Prog-
ress of fibrinolysis during tumor necrosis factor infusions in humans.
Concomitant increase in tissue-type plasminogen activator, plasmin-
ogen activator inhibitor type-1, and fibrin(ogen) degradation prod-
ucts. Blood 76: 2284–2289.
19. Jia, G., R.W. Erickson, D.F. Choy, S. Mosesova, L.C. Wu, O.D.
Solberg, A. Shikotra, R. Carter, S. Audusseau, Q. Hamid, P. Brad-
ding, J.V. Fahy, P.G. Woodruff, J.M. Harris, J.R. Arron, and Bron-
choscopic Exploratory Research Study of Biomarkers in
Corticosteroid-Refractory Asthma (BOBCAT) Study Group. 2012.
Periostin is a systemic biomarker of eosinophilic airway inflamma-
tion in asthmatic patients. The Journal of Allergy and Clinical
Immunology 130: 647–654. doi:10.1016/j.jaci.2012.06.025.
20. Kanemitsu, Y., H. Matsumoto, K. Izuhara, Y. Tohda, H. Kita, T.
Horiguchi, K. Kuwabara, K. Tomii, K. Otsuka, M. Fujimura, N.
Ohkura, K. Tomita, A. Yokoyama, H. Ohnishi, Y. Nakano, T.
Oguma, S. Hozawa, T. Nagasaki, I. Ito, T. Oguma, H. Inoue, T.
Tajiri, T. Iwata, Y. Izuhara, J. Ono, S. Ohta, M. Tamari, T. Hirota, T.
Yokoyama, A. Niimi, and M. Mishima. 2013. Increased periostin
associates with greater airflow limitation in patients receiving in-
haled corticosteroids. The Journal of Allergy and Clinical Immunol-
ogy 132: 305–312.
21. Del Prete, G., M. de Carli, R.M. Lammel, M.M. D’Elios, K.C.
Daniel, B. Giusti, R. Abbate, and S. Romagnani. 1995. Th1 and
Th2 T-helper cells exert opposite effects on procoagulant activity
and tissue factor production by human monocytes. Blood 86: 250–
257.
22. Global Initiative for Asthma (GINA) Report. Revised 2016. Global
Strategy for Asthma Management and Prevention. Available from:
www.ginasthma.org. Accessed 14 July 2016.
23. Hemker, H.C., and R. Kremers. 2013. Data management in throm-
bin generation. Thrombosis Research 131: 3–11.
24. Jankowski, M., A. Undas, P. Kaczmarek, and S. Butenas. 2011.
Activated factor XI and tissue factor in chronic obstructive pulmo-
nary disease: Links with inflammation and thrombin generation.
Thrombos i s Research 127 : 242–246 . do i :10 .1016 /
j.thromres.2010.11.005.
25. Owczarek, D., D. Cibor, K. Sałapa,M.K. Głowacki, T.Mach, andA.
Undas. 2013. Reduced plasma fibrin clot permeability and suscep-
tibility to lysis in patients with inflammatory bowel disease: A novel
prothrombotic mechanism. Inflammatory Bowel Diseases 19: 2616–
2624. doi:10.1097/01.MIB.0000437041.59208.44.
26. Yudkin, J.S., M. Kumari, S.E. Humphries, and V. Mohamed-Ali.
2000. Inflammation, obesity, stress and coronary heart disease: Is
interleukin-6 the link? Atherosclerosis 148: 209–214.
27. Jones, K.G., D.J. Brull, L.C. Brown, M. Sian, R.M. Greenhalgh,
S.E. Humphries, and J.T. Powell. 2001. Interleukin-6 (IL-6) and the
prognosis of abdominal aortic aneurysms. Circulation 103: 2260–
2265.
28. Swerdlow, D.I., M.V. Holmes, K.B. Kuchenbaecker, J.E.L.
Engmann, T. Shah, R. Sofat, Y.R. Guo, C. Chung, A. Peasey, R.P.
1234 Bazan-Socha, Mastalerz, Cybulska, Zareba, Kremers, Zabczyk, Pulka, Iwaniec, Hemker, and Undas
Ster, S.P. Mooijaart, H.A. Ireland, M. Leusink, C. Langenberg, K.
Li, J. Palmen, P. Howard, J.A. Cooper, F. Drenos, J. Hardy, M.A.
Nalls, Y.R. Li, G. Lowe, M. Stewart, S.J. Bielinski, J. Peto, N.J.
Timpson, J. Gallacher, M. Dunlop, R. Houlston, I. Tomlinson, I.
Tzoulaki, J. Luan, J.M.A. Boer, N.G. Forouhi, N.C. Onland-Moret,
Y.T. van der Schouw, R.B. Schnabel, J.A. Hubacek, R. Kubinova,
M. Baceviciene, A. Tamosiunas, A. Pajak, R. Topor-Madry, S.A.
Malyutina, D. Baldassarre, B. Sennblad, E. Tremoli, U. de Faire, L.
Ferrucci, S. Bandenelli, T. Tanaka, J.F. Meschia, A. Singleton, G.
Navis, I.M. Leach, S.J.L. Bakker, R.T. Gansevoort, I. Ford, S.E.
Epstein, M.S. Burnett, J.M. Devaney, J.W. Jukema, R.G.J.
Westendorp, G.J. de Borst, Y. van der Graaf, P.A. de Jong, A.H.
Maitland-van der Zee, O.H. Klungel, A. de Boer, P.A. Doevendans,
J.W. Stephens, C.B. Eaton, J.G. Robinson, J.E. Manson, F.G.R.
Fowkes, T.M. Frayling, J.F. Price, P.H. Whincup, R.W. Morris,
D.A. Lawlor, G.D. Smith, Y. Ben-Shlomo, S. Redline, L.A. Lange,
M. Kumari, N.J. Wareham, W.M.M. Verschuren, E.J. Benjamin,
J.C. Whittaker, A. Hamsten, F. Dudbridge, J.A.C. Delaney, A.
Wong, D. Kuh, R. Hardy, B.A. Castillo, J.J. Connolly, P. van der
Harst, E.J. Brunner, M.G. Marmot, C.L. Wassel, S.E. Humphries,
P.J. Talmud,M. Kivimaki, F.W. Asselbergs,M. Voevoda,M. Bobak,
H. Pikhart, J.G. Wilson, H. Hakonarson, A.P. Reiner, B.J. Keating,
N. Sattar, A.D. Hingorani, and J.P. Casas. 2012. The interleukin-6
receptor as a target for prevention of coronary heart disease: A
Mendelian randomisation analysis. Lancet 379: 1214–1224.
29. Onufrak, S., J. Abramson, and V. Vaccarino. 2007. Adult-onset
asthma is associated with increased carotid atherosclerosis among
women in the Atherosclerosis Risk in Communities (ARIC) study.
Atherosclerosis 195: 129–137.
30. Iribarren, C., I.V. Tolstykh, andM.D. Eisner. 2004. Are patients with
asthma at increased risk of coronary heart disease? International
Journal of Epidemiology 33: 743–748.
31. Duan, H.O., and P.J. Simpson-Haidaris. 2003. Functional analysis of
interleukin 6 response elements (IL-6REs) on the human gamma-
fibrinogen promoter: Binding of hepatic Stat3 correlates negatively
with transactivation potential of type II IL-6REs. The Journal of
Biological Chemistry 278: 41270–41281.
32. Grignani, G., and A. Maiolo. 2000. Cytokines and hemostasis.
Haematologica 85: 967–972.
33. Scarpati, E.M., and J.E. Sadler. 1989. Regulation of endothelial cell
coagulant properties. Modulation of tissue factor, plasminogen acti-
vator inhibitors, and thrombomodulin by phorbol 12-myristate 13-
acetate and tumor necrosis factor. The Journal of Biological Chem-
istry 264: 20705–20713.
34. Furie, B., and B.C. Furie. 2008.Mechanisms of thrombus formation.
NEJM 359: 938–949.
35. Chu, A.J. 2005. Tissue factor mediates inflammation. Archives of
Biochemistry and Biophysics 440: 123–132.
36. Shimizu, S., E.C. Gabazza, T. Hayashi, M. Ido, Y. Adachi, and K.
Suzuki. 2000. Thrombin stimulates the expression of PDGF in lung
epithelial cells. American Journal of Physiology. Lung Cellular and
Molecular Physiology 279: L503–L510.
37. Moffatt, J.D., C.P. Page, and G.J. Laurent. 2004. Shooting for PARs
in lung diseases. Current Opinion in Pharmacology 4: 221–229.
38. Kell, D.B., and E. Pretorius. 2015. The simultaneous occurrence of
both hypercoagulability and hypofibrinolysis in blood and serum
during systemic inflammation, and the roles of iron and fibrin(ogen).
Integrative Biology 7: 24–52. doi:10.1039/C4IB00173G.
39. Pankiw-Bembenek, O., J. Zalewski, T. Goralczyk, and A. Undas.
2012. A history of early stent thrombosis is associated with
prolonged clot lysis time. Thrombosis and Haemostasis 107: 513–
520.
40. Samad, F., T. Uysal, S. Wiesbrock, M. Pandey, S. Hotamisligil, and
J. Loskutoff. 1999. Tumor necrosis factor α is a key component in
the obesity-linked elevation of plasminogen activator inhibitor 1.
Proceedings of the National Academy of Sciences of the United
States of America 96: 6902–6907.
41. Wagener, A.H., S.B. de Nijs, R. Lutter, A.R. Sousa, E.J. Weersink,
E.H. Bel, and P.J. Sterk. 2015. External validation of blood eosino-
phils, FE(NO) and serum periostin as surrogates for sputum eosin-
ophils in asthma. Thorax 70: 115–120.
42. Górska, K., M. Maskey-Warzęchowska, P. Nejman-Gryz, P.
Korczyński, M. Prochorec-Sobieszek, and R. Krenke. 2016. Com-
parative study of periostin expression in different respiratory sam-
ples in patients with asthma and chronic obstructive pulmonary
disease. Polskie Archiwum Medycyny Wewnętrznej 126: 124–137.
doi:10.20452/pamw.3299.
43. Borth, W. 1992. Alpha 2-macroglobulin, a multifunctional binding
protein with targeting characteristics. The FASEB Journal 6: 3345–
3353.
44. Kyrle, P.A. 2014. Venous thrombosis: Who should be screened for
thrombophilia in 2014? Polskie Archiwum Medycyny Wewnętrznej
124: 65–69.
45. Undas, A., K. Zawilska, M. Ciesla-Dul, A. Lehmann-Kopydłowska,
A. Skubiszak, K. Ciepłuch, and W. Tracz. 2009. Altered fibrin clot
structure/function in patients with idiopathic venous thromboembo-
lism and in their relatives. Blood 114: 4272–4278.
1235Prothrombotic State in Asthma
